General
Osimertinib superior to gefitinib, erlotinib in first-line treatment of advanced NSCLC | News for Doctor, Nurse, Pharmacist | Oncology | MIMS Malaysia
 

Osimertinib superior to gefitinib, erlotinib in first-line treatment of advanced NSCLC | News for Doctor, Nurse, Pharmacist | Oncology | MIMS Malaysia

Shared by:

 
Osimertinib superior to gefitinib, erlotinib in first-line treatment of advanced NSCLC | MIMS Malaysia
 
specialty.mims.com
 
20 Dec 2017 - General